These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 25110297)

  • 1. Regulatory framework of pharmaceutical compounding and actual developments of legislation in Europe.
    Minghetti P; Pantano D; Gennari CG; Casiraghi A
    Health Policy; 2014 Sep; 117(3):328-33. PubMed ID: 25110297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Outlook on the European and Italian Rules to Guarantee Magistral Formulas.
    Selmin F; Casiraghi A; Musazzi UM; Fortini M; Minghetti P
    Int J Pharm Compd; 2019; 23(1):6-12. PubMed ID: 30668530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Extent of Extemporaneous Preparation and Regulatory Framework of Extemporaneous Compounding in Latvia.
    Kiseļova O; Mauriņa B; Šidlovska V; Zvejnieks J
    Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31454896
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of the Council of Europe Resolution on quality and safety assurance requirements for medicinal products prepared in pharmacies for the special needs of patients.
    Scheepers HPA; Neerup Handlos V; Walser S; Schutjens MDB; Neef C
    Eur J Hosp Pharm; 2017 Jul; 24(4):218-223. PubMed ID: 31157793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Legislation on the preparation of medicinal products in European pharmacies and the Council of Europe Resolution.
    Scheepers HP; Langedijk J; Neerup Handlos V; Walser S; Schutjens MH; Neef C
    Eur J Hosp Pharm; 2017 Jul; 24(4):224-229. PubMed ID: 31157801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compounding pharmacies: who is in charge?
    Pergolizzi JV; Labhsetwar S; LeQuang JA
    Pain Pract; 2013 Mar; 13(3):253-7. PubMed ID: 23350709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International Academy of Compounding Pharmacists' recommendations for state-based legislative and regulatory initiatives.
    Miller DG
    Int J Pharm Compd; 2013; 17(1):48-9. PubMed ID: 23627246
    [No Abstract]   [Full Text] [Related]  

  • 9. Aseptic preparation of parenteral medicinal products in healthcare establishments in Europe.
    Scheepers H; Beaney AM; Le Brun P; Neerup Handlos V; Schutjens M; Walser S; Neef C
    Eur J Hosp Pharm; 2016 Jan; 23(1):50-53. PubMed ID: 31156814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies.
    Yoch D
    Int J Pharm Compd; 2017; 21(2):95-102. PubMed ID: 28346203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The International Academy of Compounding Pharmacists: Government Affairs Lookback on 2017 Accomplishments and Look Ahead at 2018 Initiatives.
    Blankenship C
    Int J Pharm Compd; 2018; 22(1):26-28. PubMed ID: 29385383
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmaceutical counseling: Between evidence-based medicine and profits.
    Egorova SN; Akhmetova T
    Int J Risk Saf Med; 2015; 27 Suppl 1():S87-8. PubMed ID: 26639727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introduction to Quality Control in a Compounding Pharmacy.
    Allen LV
    Int J Pharm Compd; 2016; 20(6):481-484. PubMed ID: 28339387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survey of sterile product compounding practices in Canadian hospital pharmacies.
    Fitch DP; Hall KW
    Can J Hosp Pharm; 1993 Dec; 46(6):249-60. PubMed ID: 10131343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analytic Methods Used in Quality Control in a Compounding Pharmacy.
    Allen LV
    Int J Pharm Compd; 2017; 21(1):31-37. PubMed ID: 28346196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence, determinants, and characteristics of extemporaneous compounding in Jordanian pharmacies.
    AlKhatib HS; Jalouqa S; Maraqa N; Ratka A; Elayeh E; Al Muhaissen S
    BMC Health Serv Res; 2019 Nov; 19(1):816. PubMed ID: 31703672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applying Quality by Design Concepts to Pharmacy Compounding.
    Timko RJ
    Int J Pharm Compd; 2015; 19(6):453-63. PubMed ID: 26891559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unlicensed pharmaceutical preparations for clinical patient care: Ensuring safety.
    de Wilde S; de Jong MGH; Le Brun PPH; Guchelaar HJ; Schimmel KJM
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):3-8. PubMed ID: 29047193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2013 State Compounding Legislation Tracker.
    Miller DG
    Int J Pharm Compd; 2013; 17(5):375-8. PubMed ID: 24459782
    [No Abstract]   [Full Text] [Related]  

  • 20. Council of Europe Resolution CM/Res(2016)2: a major contribution to patient safety from reconstituted injectable medicines?
    Beaney AM; Le Brun P; Ravera S; Scheepers H
    Eur J Hosp Pharm; 2020 Jul; 27(4):216-221. PubMed ID: 32587080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.